The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic Cancer Society.
A study found significant improvement in progression-free survival among patients treated with the combination of bevacizumab and fosbretabulin versus bevacizumab alone, with a median improvement of 2.5 months. Researchers observed a greater improvement in progression-free survival among patients with platinum-resistant disease, with a 3.3-month improvement, but the difference in platinum-sensitive patients failed to reach statistical significance.
Read more here.
